Grasustek

Grasustek is a pegfilgrastim injection marketed in the European Union. It contains the biologic agent pegfilgrastim, a long‑acting granulocyte colony‑stimulating factor (G‑CSF) that is administered subcutaneously. The product is prescribed by healthcare professionals to support neutrophil recovery after chemotherapy. As a prescription‑only medication, Grasustek is formulated to provide sustained stimulation of bone‑marrow neutrophil production, helping to reduce the risk of infection and improve patient outcomes during cancer treatment.

Grasustek is indicated for the prophylaxis of neutropenia associated with myelosuppressive chemotherapy.

- Reduce the incidence of febrile neutropenia in patients receiving high‑risk chemotherapy regimens. - Support dose‑dense or dose‑intense chemotherapy protocols by maintaining neutrophil counts. - Facilitate timely administration of subsequent chemotherapy cycles. - May be used in patients with solid tumors or hematologic malignancies where neutropenia is a known complication.

The safety profile of pegfilgrastim reflects its pharmacologic activity on neutrophil production; side effects are categorized as common or serious.

Common: - Bone pain, especially in the lower back or hips. - Injection‑site reactions such as redness, swelling, or mild discomfort. - Fatigue or generalized weakness. - Nausea or mild gastrointestinal upset.

Serious: - Splenic rupture or enlargement. - Acute respiratory distress or severe allergic reactions (anaphylaxis). - Severe skin reactions like Stevens‑Johnson syndrome. - Unexplained fever or sepsis despite neutrophil recovery.

Before prescribing Grasustek, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Assess baseline neutrophil counts; avoid use in patients with severe neutropenia unrelated to chemotherapy. - Use caution in individuals with a history of splenic disorders or abdominal trauma. - Monitor for signs of bone pain and provide analgesia as needed. - Evaluate renal or hepatic impairment, although dose adjustment is generally not required. - Consider pregnancy status; the drug’s safety in pregnancy is not established. - Review concurrent use of other myeloid growth factors to prevent overlapping effects.

Pegfilgrastim may interact with other medications or biologics; awareness of these interactions helps optimize safety.

Avoid: - Concurrent use of other granulocyte‑colony stimulating agents (e.g., filgrastim) without clinical justification. - Live vaccines administered within 2 weeks before or after pegfilgrastim injection.

Use with caution: - Chemotherapy agents that cause profound myelosuppression; timing of pegfilgrastim administration should follow chemotherapy per guidelines. - Corticosteroids, which may mask bone‑pain symptoms. - Antimicrobial agents that affect bone‑marrow function, such as certain antimetabolites.